| 2019 | A therapeutic strategy for chemotherapy-resistant gastric cancer via destabilization of both β-catenin and ras
| 김상우, 노성훈, 백순명, 이재은, 정재호 | Article |
| 2018 | Targeting mutant KRAS with CRISPR-Cas9 controls tumor growth
| 김한상, 김형범, 백순명, 송재진, 육종인, 이민구, 차용훈, 최은창 | Article |
| 2018 | Selective Cytotoxicity of the NAMPT Inhibitor FK866 Toward Gastric Cancer Cells with Markers of the Epithelial-Mesenchymal Transition, Due to Loss of NAPRT | 김현석, 백순명, 이주영, 정재호, 최윤영 | Article |
| 2018 | Adjuvant Chemotherapy Guided by a 21-Gene Expression Assay in Breast Cancer | 백순명 | Article |
| 2018 | AIRVF: a filtering toolbox for precise variant calling in Ion Torrent sequencing | 김상우, 백순명, 이한나 | Article |
| 2018 | Tumour sidedness and intrinsic subtypes in patients with stage II/III colon cancer: analysis of NSABP C-07 (NRG Oncology) | 백순명 | Article |
| 2018 | Use of letrozole after aromatase inhibitor-based therapy in postmenopausal breast cancer (NRG Oncology/NSABP B-42): a randomised, double-blind, placebo-controlled, phase 3 trial | 백순명 | Article |
| 2018 | Establishment of a platform of non-small-cell lung cancer patient-derived xenografts with clinical and genomic annotation | 김대준, 김진아, 김혜련, 박성용, 백순명, 심효섭, 윤미란, 이진구, 이한나, 조병철, 표경호, 홍민희 | Article |
| 2018 | Neopepsee: accurate genome-level prediction of neoantigens by harnessing sequence and amino acid immunogenicity information | 김상우, 김한상, 백순명, 이민구 | Article |
| 2017 | Assessing Tumor-infiltrating Lymphocytes in Solid Tumors: A Practical Review for Pathologists and Proposal for a Standardized Method From the International Immunooncology Biomarkers Working Group: Part 1: Assessing the Host Immune Response, TILs in Invasive Breast Carcinoma and Ductal Carcinoma In Situ, Metastatic Tumor Deposits and Areas for Further Research | 백순명 | Article |
| 2017 | 21-Gene Recurrence Score and Locoregional Recurrence in Node-Positive/ER-Positive Breast Cancer Treated With Chemo-Endocrine Therapy | 백순명 | Article |
| 2017 | The Effect on Surgical Complications of Bevacizumab Added to Neoadjuvant Chemotherapy for Breast Cancer: NRG Oncology/NSABP Protocol B-40 | 백순명 | Article |
| 2017 | Complementary utility of targeted next-generation sequencing and immunohistochemistry panels as a screening platform to select targeted therapy for advanced gastric cancer
| 금웅섭, 김현기, 김형일, 김효송, 노성훈, 라선영, 박규현, 박준철, 배수진, 백순명, 범승훈, 손태일, 신성관, 이상길, 이용찬, 이은영, 이한나, 임준석, 정민규, 정재호, 정현철, 최윤영, 형우진 | Article |
| 2017 | Co-clinical trials demonstrate predictive biomarkers for dovitinib, an FGFR inhibitor, in lung squamous cell carcinoma | 김은영, 김진아, 김혜련, 백순명, 심효섭, 이진구, 조병철, 홍민희 | Article |
| 2017 | Prognosis of stage III colorectal carcinomas with FOLFOX adjuvant chemotherapy can be predicted by molecular subtype
| 김원규, 김태일, 김호근, 민병소, 박민희, 백순명, 이현정, 홍성필 | Article |
| 2017 | Effects of hormone receptor status on the durable response of trastuzumab-based therapy in metastatic breast cancer | 김건민, 김승일, 박세호, 박형석, 박형순, 백순명, 손주혁, 정현철 | Article |
| 2016 | CDX2 as a Prognostic Biomarker in Stage II and Stage III Colon Cancer
| 백순명 | Article |
| 2016 | Activation of the Met kinase confers acquired drug resistance in FGFR-targeted lung cancer therapy
| 김혜련, 백순명, 조병철, 표경호 | Article |
| 2016 | Genomic profiling of lung adenocarcinoma patients reveals therapeutic targets and confers clinical benefit when standard molecular testing is negative
| 김은영, 김혜련, 백순명, 심효섭, 임선민, 임승택, 조병철 | Article |
| 2016 | Clinical Outcome From Oxaliplatin Treatment in Stage II/III Colon Cancer According to Intrinsic Subtypes: Secondary Analysis of NSABP C-07/NRG Oncology Randomized Clinical Trial
| 백순명 | Article |
| 2016 | EGFR-Mediated Reactivation of MAPK Signaling Induces Acquired Resistance to GSK2118436 in BRAF V600E-Mutant NSCLC Cell Lines
| 김민환, 김주항, 김혜련, 문용화, 백순명, 임선민, 조병철 | Article |
| 2015 | Phase II clinical and exploratory biomarker study of dacomitinib in recurrent and/or metastatic esophageal squamous cell carcinoma
| 김대준, 김주항, 김현기, 김혜련, 김효송, 문용화, 박준철, 백순명, 신성관, 이상길, 이용찬, 이창걸, 정현수, 조병철, 표경호, 허진 | Article |
| 2015 | Antitumor Activity and Acquired Resistance Mechanism of Dovitinib (TKI258) in RET-Rearranged Lung Adenocarcinoma
| 강찬우, 강한나, 김대준, 김주항, 김혜련, 김환, 문용화, 백순명, 윤미란, 임선민, 장강원, 조병철, 표경호 | Article |
| 2015 | Prognostic Tests for Estrogen Receptor-Positive Breast Cancer: Need for Global Consideration and Further Evolution | 김승일, 김지예, 백순명 | Article |
| 2015 | Neoadjuvant plus adjuvant bevacizumab in early breast cancer (NSABP B-40 [NRG Oncology]): secondary outcomes of a phase 3, randomised controlled trial | 백순명 | Article |
| 2015 | A polygenic risk score for breast cancer in women receiving tamoxifen or raloxifene on NSABP P-1 and P-2 | 백순명 | Article |
| 2015 | Phase II clinical and exploratory biomarker study of dacomitinib in patients with recurrent and/or metastatic squamous cell carcinoma of head and neck | 고윤우, 권형주, 김주항, 김한상, 김혜련, 백순명, 이민구, 이지현, 정인경, 조병철, 최은창 | Article |
| 2015 | Nanomaterials for theranostics: Recent advances and future challenges | 백순명, 허용민 | Article |
| 2015 | Intrinsic subtypes, PIK3CA mutation, and the degree of benefit from adjuvant trastuzumab in the NSABP B-31 trial | 백순명 | Article |
| 2015 | Prospective Validation of a 21-Gene Expression Assay in Breast Cancer
| 백순명 | Article |
| 2015 | Cancer Cell Line Panels Empower Genomics-Based Discovery of Precision Cancer Medicine
| 김현석, 백순명, 성여진 | Article |
| 2014 | Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis. | 백순명 | Article |
| 2013 | Predicting Degree of Benefit From Adjuvant Trastuzumab in NSABP Trial B-31 | 백순명 | Article |
| 2013 | Defective Mismatch Repair and Benefit from Bevacizumab for Colon Cancer: Findings from NSABP C-08 | 백순명 | Article |
http://orcid.org/0000-0001-9688-6480
(Yonsei Health Research Network)
(34977365100)
